Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx “donut hole” coverage demo

Executive Summary

Medicare Part D supplemental drug coverage demonstration project allowing drug plans to cover the "donut hole" is announced in Feb. 25 1Federal Register notice. Prescription drug plans offering enhanced alternative coverage would receive a capitated drug reinsurance payment instead of specific reinsurance payments of 80% of drug costs after a beneficiary has reached the catastrophic coverage level. The plan may fill the "donut hole" in part or in its entirety and must provide catastrophic drug coverage. Medicare Advantage drug plans may choose to fill the coverage gap using Part A or Part B rebate dollars. Health insurers worked with the Centers for Medicare & Medicaid Services to have the demo project developed (2"The Pink Sheet" Jan. 24, 2005, p. 14)...

You may also be interested in...



“Donut Hole” Waiver Planned By CMS; Merck Legacy Helps Medco In Part D

CMS is developing a waiver process that would provide up-front, capitated catastrophic coverage payments to Medicare Part D sponsors that design plans to fill in the "donut hole" coverage gap

India Proposes Tiered Approach To Oversee Genome Editing

India has proposed three categories for grouping genetically edited organisms based on the complexity of modifications.

A Runaway Hit In US, Pfizer Gains EU Nod for Vyndaqel In Cardiomyopathy

Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.

Topics

UsernamePublicRestriction

Register

PS045435

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel